Abstract 784P
Background
Choriocarcinoma (CC) is a rare and highly aggressive cancer that exists in both the gestational (GCC) and non-gestational (NGCC) forms. Our research focused on comparing clinical outcomes, response to therapy, and prognostic determinants between these subtypes.
Methods
We analyzed data from the SEER database of patients diagnosed with CC between 2000 and 2020. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test were used for clinical features comparison. Kaplan-Meier estimation, log-rank tests, and Cox regression analyses were used to identify prognostic factors for overall survival (OS) and cancer specific survival (CSS). A nomogram was developed to predict 5-year OS, and a calibration curve was plotted to evaluate the agreement between the actual (observed) outcomes and expected probabilities.
Results
Of the 719 patients studied, 520 had GCC, and 200 had NGCC. Younger individuals were more common in the GCC. Additionally, a higher percentage of patients with NGCC were married (63.0% vs. 52.6%). AJCC stage distribution also differed; 47.4% of GCC patients were at stage I compared to 6.0% of NGCC patients. The surgery rates were higher in the NGCC group (79.5% vs. 60.9%). Patients with GCC had better OS than those with NGCC (93% vs. 71.2%, p = 0.001). CSS rates were 66.8% for NGCC and 65.2% for GCC (p = 0.001).
We developed a prognostic nomogram that integrated significant variables from multivariate analysis. For GCC, the model assigned the highest weight to radiation, followed by metastasis, and marital status. The AUC was 0.711 (95% CI: 0.64–0.79), and the calibration curves exhibited a mean error of 0.015. The NGCC model assigned the highest weights to metastasis, chemotherapy, and age. The AUC was 0.837 (95% CI, 0.77–0.9), and the calibration curve for 5-year survival demonstrated a mean error of 0.01.
Conclusions
Our study highlights the significant clinical and survival differences between GCC and NGCC patients. We developed prognostic nomograms tailored to each subtype to enhance prediction and support personalized management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
880P - Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial
Presenter: Thorsten Fuereder
Session: Poster session 02
881P - Cetuximab with dalpicilib in patients with HPV-negative, anti-PD-1 resistant R/M HNSCC
Presenter: Ju Houyu
Session: Poster session 02
882P - Quitting smoking after diagnosis of head and neck cancer is associated with reduced risk of mortality: A multicentric prospective cohort study
Presenter: Mahdi Sheikh
Session: Poster session 02
883P - Oral rehabilitation after mandibular reconstruction for head and neck malignancy: A multicenter study
Presenter: lise marie Roussel
Session: Poster session 02
884P - Real-world treatment patterns and survival outcomes associated with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A German claims data analysis
Presenter: Thomas Kuhnt
Session: Poster session 02
885P - Different patterns of treatment failure between p16+ and p16- patients affected by oropharyngeal carcinoma (OPC) undergoing (chemo)radiation
Presenter: Riccardo Gili
Session: Poster session 02
887P - Treatment of elderly patients with locally advanced laryngeal carcinoma with dose-intense chemotherapy followed by radio-chemotherapy: Evading surgical intervention
Presenter: Maher Salamoon
Session: Poster session 02
888P - Comparing paclitaxel plus cisplatin versus cisplatin in concurrent chemoradiotherapy for stage IV locoregionally advanced nasopharyngeal carcinoma: A phase II randomized trial
Presenter: Ling Guo
Session: Poster session 02